AFYA

Afya Ltd

Add to Watchlist

Advanced Chart

14.470

-0.16(-1.094%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

14.793

Open

14.710

VWAP

14.50

Vol

70.01K

Mkt Cap

1.36B

Low

14.4108

Amount

1.02M

EV/EBITDA(TTM)

6.69

Total Shares

88.06M

1.72B

EV/OCF(TTM)

6.56

P/S(TTM)

2.22

Afya Ltd is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. The Company's methodological approach combines integrated content, interactive learning, and an adaptive experience for learners. Through its educational content and technology-enabled activities, the Company focuses on personalized learning that mirrors one-on-one tutoring. The Company's undergraduate and graduate campuses are spread across Brazil, as well as its digital medical platform.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

936.22M

+15.6%

2.287

-0.13%

937.04M

+11.4%

1.928

+7.73%

931.83M

+9.75%

2.105

+0.25%

Estimates Revision

The market is revising Upward the revenue expectations for Afya Limited (AFYA) for FY2025, with the revenue forecasts being adjusted by 0.64% over the past three months. During the same period, the stock price has changed by -22.66%.

Revenue Estimates for FY2025

Revise Upward

+0.64%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.41%

In Past 3 Month

Stock Price

Go Down

-22.66%

In Past 3 Month

3 Analyst Rating

42.85% Upside

Wall Street analysts forecast AFYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AFYA is 20.67 USD with a low forecast of 19.00 USD and a high forecast of 23.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

1 Sell

Moderate Sell

42.85% Upside

Current: 14.470

Low

19.00

Averages

20.67

High

23.50

42.85% Upside

Current: 14.470

Low

19.00

Averages

20.67

High

23.50

UBS

Neutral

maintain

2025-06-12

Reason

UBS

Price Target

2025-06-12

maintain

Neutral

Reason

UBS raised the firm's price target on Afya to $19.50 from $17.50 and keeps a Neutral rating on the shares. Positive momentum on growth and margins seems fairly priced in, the analyst tells investors in a research note.

Morgan Stanley

Mauricio Cepeda

Hold

Sell

Downgrades

$19 → $17

2025-03-11

Reason

Morgan Stanley

Mauricio Cepeda

Price Target

$19 → $17

2025-03-11

Downgrades

Hold

Sell

Reason

Citigroup

Leandro Bastos

Hold

Strong Sell

Downgrades

$18 → $15

2025-01-31

Reason

Citigroup

Leandro Bastos

Price Target

$18 → $15

2025-01-31

Downgrades

Hold

Strong Sell

Reason

JP Morgan

Marcelo Santos

Hold

Maintains

$25 → $21

2025-01-17

Reason

JP Morgan

Marcelo Santos

Price Target

$25 → $21

2025-01-17

Maintains

Hold

Reason

Goldman Sachs

Gustavo Miele

Strong Sell

Initiates

$16

2024-12-03

Reason

Goldman Sachs

Gustavo Miele

Price Target

$16

2024-12-03

Initiates

Strong Sell

Reason

Goldman Sachs initiated coverage of Afya with a Sell rating and $16 price target. Afya is the largest medical education ecosystem in Brazil, the analyst tells investors in a research note. The firm says Afya's integration skills, solid brands, scale and relatively light balance sheet position the company as the main consolidator in the market, but it remains cautious on the economics of undergrad medical seats. AFYA's valuation premium to the rest of the sector is stretched at current levels, contends Goldman.

UBS

Andre Salles

Hold

Initiates

$20

2024-08-30

Reason

UBS

Andre Salles

Price Target

$20

2024-08-30

Initiates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Afya Ltd (AFYA.O) is 8.65, compared to its 5-year average forward P/E of 15.67. For a more detailed relative valuation and DCF analysis to assess Afya Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

15.67

Current PE

8.65

Overvalued PE

22.53

Undervalued PE

8.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

9.60

Current EV/EBITDA

5.41

Overvalued EV/EBITDA

13.67

Undervalued EV/EBITDA

5.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

3.61

Current PS

1.91

Overvalued PS

5.72

Undervalued PS

1.51